Data at ASCO Showcase Sanofi's Commitment to Research and Identify Treatments for Cancer Patients

Iniparib and Semuloparin Phase III Data Selected for Oral Presentation and Best of ASCO

Paris, France – May 19, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that data from eight compounds in the company's robust oncology portfolio will be showcased in more than 100 abstracts at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.

Data presentations highlight the Sanofi Oncology pipeline in both solid tumors and hematologic malignancies. New research from early through late stage development will be reported, including data on cabazitaxel, docetaxel and oxaliplatin, as well as on investigational compounds iniparib and semuloparin.

"Sanofi fully supports this year's ASCO Presidential Theme - Patients, Pathways and Progress. Our connection to the patient inspires us to partner with leading experts to exchange ideas that will help us discover innovative solutions to improve patient outcomes," said Debasish Roychowdhury, MD, Senior Vice President and Head of Global Oncology Division. *"Sanofi is committed to ASCO and its mission."*

Abstract titles of presentations selected for Best of ASCO include:
The 2011 Best of ASCO Meetings feature the most relevant and cutting-edge science in oncology research.

- Abstract #1007: Monday, June 6, 2011, 11:00-11:15am CDT: A Randomized Phase III Study of Iniparib (BSI-201) in combination with Gemcitabine (G) and Carboplatin (C) in Metastatic Triple Negative Breast Cancer (mTNBC).
  - Joyce O'Shaughnessy, MD, Baylor-Charles A. Sammons Cancer Center
  - Breast Cancer – Triple-negative/Cytotoxics/Local Therapy Oral Abstract Session, Hall B1.

- Abstract #LBA9014: Monday, June 6, 2011, 2:45-3:00pm CDT: The ultra-low-molecular-weight heparin (ULMWH) Semuloparin for Prevention of Venous Thromboembolism (VTE) in Cancer Patients Receiving Chemotherapy: SAVE ONCO Study.
  - Giancarlo Agnelli, MD, University of Perugia, Italy
  - Patient and Survivor Care Oral Abstract Session, S404.

Abstract titles of other notable data accepted for presentation at the ASCO meeting include:

- Abstract #5004: Saturday, June 4, 2011, 3:15-3:30pm CDT: A Phase II Trial of Iniparib (BSI-201) in combination with Gemcitabine/Carboplatin (GC), in Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
  - Richard T. Penson, MD, MRCP, Massachusetts General Hospital
  - Gynecological Cancer Oral Abstract Session, E354a.

- Abstract #5005: Saturday, June 4, 2011, 3:30-3:45pm CDT: A Phase II Trial of Iniparib (BSI-201) in combination with Gemcitabine/Carboplatin (GC), in Patients with Platinum-Resistant Recurrent Ovarian Cancer.
  - Michael J. Birrer, MD, PhD, Massachusetts General Hospital
  - Gynecological Cancer Oral Abstract Session, E354a.

- Abstract #4525: Saturday, June 4, 2011, 2:00-6:00pm: Survival Benefit from First Docetaxel Treatment for Cabazitaxel plus Prednisone Compared with Mitoxantrone plus Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Enrolled in the TROPIC Trial.
  - A. Oliver Sartor, MD, Tulane School of Medicine
  - Genitourinary Cancer Poster Discussion Session, E450a, Poster #5.

- Abstract #4526: Saturday, June 4, 2011, 2:00-6:00pm CDT: A Subgroup Analysis of the TROPIC Trial Exploring Reason for Discontinuation of Prior Docetaxel and Survival Outcome of Cabazitaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC).
  - Johann Sebastian De Bono MD, The Royal Marsden Hospital, UK
  - Genitourinary Cancer Poster Discussion Session, E450a, Poster #6.

About Iniparib (BSI-201)

BSI-201 is a novel investigational oncology agent that is in Phase III trials for patients with squamous non-small cell lung cancer, as well as in Phase II trials for patients with breast, lung and other cancers. Iniparib is the United States Adopted Name (USAN) for BSI-201.

About Cabazitaxel

Cabazitaxel is a semi-synthetic taxane and works differently than docetaxel and paclitaxel. An antineoplastic agent, it acts by disrupting the microtubular network in cells. It binds to tubulin and promotes the assembly of tubulin into microtubules while simultaneously inhibiting their disassembly. This leads to the stabilization of microtubules. Cabazitaxel demonstrated a broad spectrum of antitumor activity against advanced solid tumours xenografted in mice. Cabazitaxel is active in docetaxel sensitive tumors. In addition, cabazitaxel demonstrated activity in tumour models insensitive to chemotherapy, including docetaxel.

About Semuloparin

Semuloparin is an investigational, selectively engineered anticoagulant that belongs to the ultra-low-molecular-weight heparin (ULMWH) class. Semuloparin has a novel anti-thrombotic profile resulting from an enriched antithrombin binding site and high-activity against factor Xa and residual activity against factor IIa. A large phase III clinical study (SAVE ONCO study) investigated semuloparin in cancer patients receiving chemotherapy that has been completed. The SAVE ONCO study assessed the efficacy and safety of semuloparin for the prevention of symptomatic VTE, Pulmonary Embolism and VTE related death in cancer patients receiving chemotherapy. There is currently no product registered in this indication.

About BiPar Sciences

BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. Located in South San Francisco, California, BiPar is a wholly owned subsidiary of Sanofi. For more information, please visit www.biparsciences.com.

About Sanofi Oncology

Based in Cambridge, Massachusetts, and Vitry, France, Sanofi Oncology is translating science into effective cancer therapeutics to address unmet medical needs for patients with cancer. Starting with a deep understanding of the mechanisms by which cancer develops, grows and spreads, the company employs innovative approaches in drug discovery, clinical development and partnerships to bring the right medicines to the right patients with the goal of helping cancer patients live healthier and longer lives.

Sanofi Oncology is committed to the pursuit of science and innovative cancer therapies. We believe in partnership with leading experts, and combining that expertise with our own internal scientific strength and heritage. There are currently more than 10 compounds in clinical development including small molecules and biological agents.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Oncology Division Communications
Lauren Musto
Tel: 1 (617) 665-4618
E-mail: lauren.musto@sanofi.com

Investor Relations
Sébastien Martel
Tel.: + (33) 1 53 77 45 45
E-mail: ir@sanofi.com

Corporate Media Relations
Marisol Peron
Tel: +33 (0) 1 53 77 45 02
Mobile: +33 (0) 6 08 18 94 78
E-mail: marisol.peron@sanofi.com